Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) gapped down before the market opened on Friday . The stock had previously closed at $0.11, but opened at $0.12. Hemispherx BioPharma shares last traded at $0.11, with a volume of 6455452 shares traded.
Separately, Ascendiant Capital Markets set a $1.00 price objective on shares of Hemispherx BioPharma and gave the company a “buy” rating in a research report on Friday, May 17th.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last released its quarterly earnings data on Thursday, May 16th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter.
ILLEGAL ACTIVITY NOTICE: “Hemispherx BioPharma (HEB) Shares Gap Down to $0.12” was published by Rockland Register and is the property of of Rockland Register. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://rocklandregister.com/2019/05/31/hemispherx-biopharma-heb-shares-gap-down-to-0-12.html.
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.